Article Text

Download PDFPDF

386 Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
  1. Rebecca Kristeleit1,
  2. Cara Mathews2,
  3. Andrés Redondo3,
  4. Joice Huang4,
  5. Laurie Eliason4,
  6. Ellie Im4 and
  7. Jubilee Brown5
  1. 1Guy’s and St. Thomas Hospitals, NHS Foundation Trust
  2. 2Women and Infants Hospital of Rhode Island
  3. 3Hospital Universitario La Paz – Idipaz
  4. 4Glaxosmithkline
  5. 5Levine Institute, Atrium Health


Introduction/Background PROs enable direct measurement of the experiences of pts with cancer related to an intervention. Regulators increasingly use PROs to inform the risks and benefits of new drug candidates, focusing on 3 core concepts: physical functioning (PF), disease-related symptoms (DRS), and symptomatic adverse events (AEs).

Dostarlimab is an investigational anti–programmed death-1 monoclonal antibody that has shown activity in pts with advanced dMMR EC (objective response rate, 42%; disease control rate, 58%) and an acceptable safety profile. Here, we report on PROs in pts treated with dostarlimab in the single-arm GARNET trial.

Methodology Pts with recurrent or advanced dMMR/MSI-H EC that progressed on a platinum regimen received 500 mg Q3W*4 of dostarlimab, then 1000 mg Q6W until disease progression or discontinuation (DC). PRO assessment, an exploratory endpoint, was measured using the EORTC-QLQ-C30. PROs were collected at baseline (BL), each dose cycle, and after DC. For PF and DRS (pain and fatigue), we conducted multi-item descriptive analyses, including change from BL. For symptomatic AEs and tolerability (nausea, vomiting, constipation, diarrhoea, tiredness/fatigue), we conducted item-level analyses to understand response distribution and change in response categories from BL: improved, stable, and 1-, 2-, or 3-category worsening.

Results PRO data were available for 66/104 pts who received ≥1 dose of dostarlimab. Questionnaire compliance was consistent across domains, ranging from 100% at BL to 45% at cycle 7. Pain, fatigue, and PF were maintained above BL starting at cycles 1, 3, and 4, respectively. Symptomatic AEs were experienced by a minority of pts, with <25% and <6% of pts having 1- or ≥2-category worsening, respectively. Improved scores were reported by 6% to 37% of pts.

Conclusions PROs from the GARNET trial showed that dostarlimab was generally well tolerated and disease-related symptoms were improved or maintained while on treatment. These data, along with the efficacy and safety profile of dostarlimab, support use of dostarlimab in pts with dMMR/MSI-H advanced EC.

Disclosures Clinical trial registration: NCT02715284

Funding: GlaxoSmithKline, Waltham, MA, USA

Encore statement: This data is presented on behalf of the original authors with their permission. Presented at European Society for Medical Oncology (ESMO) annual meeting, September 19–21, 2020, Virtual.

Dr. Kristeleit reports personal fees from Tesaro.

Dr. Mathews reports institutional grants from Tesaro.

Dr. Redondo reports institutional research funding from PharmaMar, Roche, and Eisai; and advisory roles at PharmaMar, AstraZeneca, Tesaro, Roche, and Eisai.

Dr. Brown reports honoraria from Olympus; consulting or advisory role at Caris, Tesaro, Clovis, AstraZeneca, and Genentech; and speakers’ bureau at Clovis.

Drs. Huang, Eliason, and Im are employees of GlaxoSmithKline.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.